Axel Benner

29PUBLICATIONS

125CO-AUTHORS

Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Stochastic analysis and modellingMedical infection agents (incl. prions)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (29)

Sort by Publication Date:

|May 21, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|Jan 06, 2026

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Hartmut Döhner, Daniela Späth, Maral Saadati

|Nov 11, 2025

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Tim Richardson, Elias Mai, Ekaterina Menis

|Oct 28, 2025

Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data.

Kaya Miah, Jelle J Goeman, Hein Putter

|Dec 09, 2024

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Elias K Mai, Uta Bertsch, Ema Pozek

|Sep 30, 2024

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Frank G Rücker, Lars Bullinger, Sibylle Cocciardi

Pageof 5

Frequent Collaborators

Hartmut Goldschmidt

Elias Mai

Hans Salwender

Hartmut Döhner

Lisa B Leypoldt

Katja C Weisel

Konstanze Döhner

Christof Scheid

Katharina S Götze

Jenny Chang-Claude

Frequent Collaborators

Hartmut Goldschmidt

Elias Mai

Hans Salwender

Hartmut Döhner